Ten-year trend of opioid and nonopioid analgesic use in the French adult population.
France
addictovigilance
analgesics
drug utilization
nonopioids
opioids
prevalence
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
01
2020
revised:
15
05
2020
accepted:
24
05
2020
pubmed:
5
6
2020
medline:
29
7
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Analgesics are the most widely used medicines worldwide. In parallel, opioid abuse has increased and is of major concern. The accessibility of pharmacologically powerful medicines and the addictovigilance signals in France about the risk of opiates addiction call for an overview of analgesic use. The objective of this study was to investigate the use of analgesics reimbursed in France over a 10-year period through its prevalence. A cross-sectional study repeated yearly was conducted by using data from the French reimbursement database from 2006 to 2015. Analgesics were classified according to their pharmacological potency: prevalence of use for each category and sociodemographic characteristics of patients treated were analysed. The annual prevalence of analgesic use was high and increased during the study period (59.8%, 253 976 users in 2015). In 2015, prevalence was always higher in women and increased with age, except for those older than 84 years. Peripheral analgesics were the most used (55.3%, 234 739 users). The prevalence of weak analgesic use decreased (21.3%, 90 257 users), mainly due to the definitive withdrawal of dextropropoxyphene in France in 2011, which was not offset by an increase in the consumption of other weak analgesics. For strong analgesics (1.2%, 5129 users), morphine was the most widely used, with a dramatic increase in oxycodone use, especially in the elderly. The prevalence of analgesic use is high: approximately 31 million adults had at least 1 analgesic reimbursed in 2015. The most widely used analgesics were peripheral analgesics, far ahead of opioid analgesics.
Substances chimiques
Analgesics, Non-Narcotic
0
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-564Subventions
Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
ID : 2015-5038
Organisme : French Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Chang HY, Daubresse M, Kruszewski SP, Alexander GC. Prevalence and treatment of pain in EDs in the United States, 2000 to 2010. Am J Emerg Med. 2014;32(5):421-431.
Christie D. 'The analgesic abuse syndrome': an epidemiological perspective. Int J Epidemiol. 1978;7(2):139-143.
Lalic S, Ilomaki J, Bell JS, Korhonen MJ, Gisev N. Prevalence and incidence of prescription opioid analgesic use in Australia. Br J Clin Pharmacol. 2019;85(1):202-215.
Tyndale RF, Sellers EM. Opioids: the painful public health reality. Clin Pharmacol Ther. 2018;103(6):924-935.
Anonymous. Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: 2010. URL: https://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf (Last accessed 13 May 2020).
Curtis JR, Xie F, Smith C, et al. Changing trends in opioid use among patients with rheumatoid arthritis in the United States. Arthritis Rheumatol. 2017;69(9):1733-1740.
Garcia del Pozo J, Carvajal A, Viloria JM, Velasco A, Garcia del Pozo V. Trends in the consumption of opioid analgesics in Spain. Higher increases as fentanyl replaces morphine. Eur J Clin Pharmacol. 2008;64(4):411-415.
Hauser W, Schug S, Furlan AD. The opioid epidemic and national guidelines for opioid therapy for chronic noncancer pain: a perspective from different continents. Pain Rep. 2017;2:e599.
Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther. 2010;88:307-317.
Morley KI, Ferris JA, Winstock AR, Lynskey MT. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain. 2017;158:1138-1144.
Wegrzyn EL, Chaghtai AM, Argoff CE, Fudin J. The CDC opioid guideline: proponent interpretation has led to misinformation. Clin Pharmacol Ther. 2018;103(6):950-953.
Ministère des Affaires sociales de la Santé et des Droits des femmes. Douleur.L'action des pouvoirs publics. URL: https://solidarites-sante.gouv.fr/soins-et-maladies/prises-en-charge-specialisees/douleur/article/l-action-des-pouvoirs-publics. 2015 (Last accessed 13 May 2020).
Chenaf C, Kabore JL, Delorme J, et al. Prescription opioid analgesic use in France: trends and impact on morbidity-mortality. Eur J Pain. 2019;23:124-134.
Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol. 2018;84:1324-1334.
Bismuth S, Leng EL, Oustric S, Montastruc JL, Lapeyre-Mestre M. Which analgesic after dextropropoxyphene withdrawal? A survey in a sample of general practitioners in southwest of France. Therapie. 2011;66:25-28.
Gedeborg R, Svennblad B, Holm L, et al. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf. 2017;26:518-527.
Titchen T, Cranswick N, Beggs S. Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. Br J Clin Pharmacol. 2005;59:718-723.
Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clin Drug Investig. 2012;32:53-63.
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286-290.
Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65:S149-S167.
Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954-962.
Duong M, Gulmez SE, Salvo F, et al. Usage patterns of paracetamol in France. Br J Clin Pharmacol. 2016;82:498-503.
Bosco-Levy P, de Boissieu P, Gouverneur A, et al. National trends in use and costs of oral anticancer drugs in France: an 8-year population-based study. Pharmacoepidemiol Drug Saf. 2017;26:1233-1241.
Dupui M, Micallef J, Lapeyre-Mestre M. Interest of large electronic health care databases in addictovigilance: lessons from 15 years of pharmacoepidemiological contribution. Therapie. 2019;74:307-314.
Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36:411-417.
WHO Collaborating Centre for Drug Statistics Methodology. Comparison of the WHO ATC classification & EphMRA/PBIRG anatomical classification, 2016. URL: https://www.ephmra.org/media/1082/who-atc-2016-comparison.pdf (Last accessed 13 May 2020).
Nordmann S, Pradel V, Lapeyre-Mestre M, et al. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician. 2013;16:89-100.
Dupouy J, Palmaro A, Fatseas M, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15:355-358.
ANSM. Nimésulide: restriction des indications thérapeutiques suite à une réévaluation européenne du rapport bénéfice/risque - Lettre aux professionnels de santé, 12 juin 2012. URL: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Nimesulide-restriction-des-indications-therapeutiques-suite-a-une-reevaluation-europeenne-du-rapport-benefice-risque-Lettre-aux-professionnels-de-sante (Last accessed 13 May 2020).
Gnjidic D, Blyth FM, Le Couteur DG, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) in older people: prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain. 2014;155:1814-1820.
Feng X, Wang X. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: a network meta-analysis. Mol Pain. 2018;14:1744806918770320.
Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015;16:28.
ANSM. Spécialités contenant du dextropropoxyphène: retrait du marché le 1er mars 2011 - Lettre aux professionnels de santé, 16 février 2011 URL: http://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Specialites-contenant-du-dextropropoxyphene-retrait-du-marche-le-1er-mars-2011-Lettre-aux-professionnels-de-sante (Last accessed 13 May 2020).
Gaubert S, Vie M, Damase-Michel C, Pathak A, Montastruc JL. Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption. Fundam Clin Pharmacol. 2009;23:247-252.
European Medicines Agency. Dextropropoxyphene, 2011. URL: https://www.ema.europa.eu/en/medicines/human/referrals/dextropropoxyphene (Last accessed 13 May 2020).
Food and Drug Administration. fda-drug-safety-communication-fda-recommends-against-continued-use-propoxyphene. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-recommends-against-continued-use-propoxyphene, 2010 (Last accessed 13 May 2020).
Pauly V, Pradel V, Frauger E, Micallef J, Thirion X. Evolution of opioids reimbursement since 2004 from the National Database of the general health insurance system. Therapie. 2011;66:369-372.
Gisev N, Pearson SA, Blanch B, et al. Initiation of strong prescription opioids in Australia: cohort characteristics and factors associated with the type of opioid initiated. Br J Clin Pharmacol. 2016;82:1123-1133.
Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC. Prescription opioid abuse in the UK. Br J Clin Pharmacol. 2013;76:823-824.
Griffiths P, Mounteney J, Lopez D, Zobel F, Gotz W. Addiction research centres and the nurturing of creativity. Monitoring the European drug situation: the ongoing challenge for the European monitoring Centre for Drugs and Drug Addiction (EMCDDA). Addiction. 2012;107:254-258.
King NB, Fraser V, Boikos C, Richardson R, Harper S. Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review. Am J Public Health. 2014;104:e32-e42.
Baumevieille M, Daveluy A, Maurain C, Bégaud B, Haramburu F. Medicines submitted to narcotics regulations in France, 1992-2007. Fundam Clin Pharmacol. 2009;23:345-349.
Daveluy A, Sauvaget L, Bastien A, et al. Tamper-resistant prescription forms for narcotics in France: should we generalize them? Fundam Clin Pharmacol. 2018;32:571-577.
Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Signal identification in addictovigilance: the functioning of the French system. Therapie. 2015;70:113-131.
Ponte C, Lepelley M, Boucherie Q, et al. Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018;187:88-94.
Frauger E, Pochard L, Boucherie Q, et al. Surveillance system on drug abuse: interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017;72:491-501.
Micallef J, Pauly V, Ponte C, et al. French pharmacosurveillance of opioid analgesics: results of disproportionality analysis from OPPIDUM (observation of psychoactive substance consumption). Fundam Clin Pharmacol. 2018;32:20-20.
ANSM. Commission des stupéfiants et psychotropes. Compte rendu de la séance du 11 mai 2017. Journée d'échange partenarial sur l'usage des antalgiques opioïdes en France URL: https://www.ansm.sante.fr/var/ansm_site/storage/original/application/7eeb7817c7212668cafbac08023063c8.pdf (Last accessed 13 May 2020).
Jouanjus E, Guernec G, Lapeyre-Mestre M, French Addictovigilance Network. Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018;32:306-322.
Peyrière H, Nogue E, Eiden C, Frauger E, Charra M, Picot MC. Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area. Fundam Clin Pharmacol. 2016;30:466-475.
Frauger E, Kheloufi F, Boucherie Q, et al. Interest of take-home naloxone for opioid overdose. Therapie. 2018;73:511-520.
Jouanjus E, Falcou A, Deheul S, Roussin A, Lapeyre-Mestre M. Detecting the diverted use of psychoactive drugs by adolescents and young adults: a pilot study. Pharmacoepidemiol Drug Saf. 2018;27:1286-1292.
Roussin A, Doazan-d'Ouince O, Géniaux H, Halberer C, French Network of Centre for Evaluation Information on Pharmacodependence. Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example. Therapie. 2015;70:203-221.
Roussin A, Palmaro A, Lapeyre-Mestre M. Weak Opioid Analgesics Abuse and Addiction: A Comparison of the Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and Tramadol. In: Preedy V, ed. Neuropathology of Drug Addictions and Substance Misuse. San Diego: Academic Press; 2016:375-391.
Pauly V, Pradel V, Pourcel L, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012;126:13-20.
Aknouche F, Guibert E, Tessier A, Alvarez JC, Lemaire-Hurtel AS, Kintz P. Unusual deaths in France: about 3 cases involving oxycodone. Toxicologie Analytique et Clinique. 2015;27:52-56.
Cicero TJ, Ellis MS, Kasper ZA. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs. Pain. 2016;157:1232-1238.
Ojanpera I, Kriikku P, Vuori E. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. Int J Leg Med. 2016;130:1209-1216.
Société française d'évaluation et de traitement de la douleur (SFETD). Utilisation des opioïdes forts dans la douleur chronique non cancéreuse chez l'adulte, 2016. URL: https://www.sfetd-douleur.org/wp-content/uploads/2019/06/recos_opioides_forts_sfetd_version_longue.compressed.pdf (Last accessed 13 May 2020).
Centers For Disease Control and Prevention, Prevention Public Health Service USDOH, Human S. Guideline for Prescribing Opioids for Chronic Pain. J Pain Palliat Care Pharmacother. 2016;30:138-140.
Volkow ND, McLellan AT. Opioid abuse in chronic Pain--misconceptions and mitigation strategies. N Engl J Med. 2016;374:1253-1263.
Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance network? Fundam Clin Pharmacol. 2018;32:643-651.
Henry SG, Bell RA, Fenton JJ, Kravitz RL. Communication about chronic pain and opioids in primary care: impact on patient and physician visit experience. Pain. 2018;159:371-379.
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260-1269.
Gahr M, Franke B, Freudenmann RW, Kolle MA, Schonfeldt-Lecuona C. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7:147-149.
Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80(2):118-122.
Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-953.
Montastruc F, Benevent J, Touafchia A, et al. Atropinic (anticholinergic) burden in antipsychotic-treated patients. Fundam Clin Pharmacol. 2018;32(1):114-119.
Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156:569-576.